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“AIDS isn’t just a disease. It’s a symptom of something deeper which has 
gone wrong within the global family. It reveals our broken relationship, 
between individuals, communities and nations…  
AIDS insists that it is time for us to sit down and address all the things we 
have kept quiet about – sexuality, poverty, and the way we handle our 
relationships from the family level to the global level/” 
 







HIV-1 specific CD4+ T cell activity in clade C infected subjects has not been 
studied. CD4+ T cells play a vital role in controlling infectious diseases and there 
is a need to augment our knowledge of HIV immunology to aid vaccine design. 
We therefore embarked on a study to characterize HIV-1 specific CD4+ T cell 
activity in both adults and infants; assess the relationship between CD4+ and 
CD8+ immune responses; and the relationship between CD4+ T cell activity and 
markers of disease progression (viral loads and CD4 counts). Our study revealed 
that the magnitude of CD8+ T cell responses correlated significantly with CD4+ T 
cell responses, but that the percentage of CD8+ T cells directed against HIV-1 
was always greater than that of CD4+ T cells. Gag was the frequently targeted 
HIV-1 protein by CD4+ T cells and had the highest density of epitopes targeted 
by CD4+ T cells. Patients with either a dominant  CD4 or CD8 T cell response 
against Gag had significantly lower viral loads than patients in whom non-Gag 
proteins were the main target (p< 0.0001 for CD4 activity and p= 0.007 for CD8 
responses). Single IFN-γ producing CD4+ T cells were present in significantly 
higher numbers than cells producing both IFN-γ and IL-2 simultaneously 
(p=0.009). Gag also dominated the CD4+ T cell response in acutely infected 
infants with IFN-γ production detected more frequently than IL-2 or TNF-α. 
Longitudinal analysis of infants receiving early ARV treatment and then ceasing 
after 12 months revealed that early treatment conferred no protection against 
increasing viremia and disease progression. CD4+ T cell responses were 





response in the face of constant exposure to high levels of viremia. Taken 
together, the data reveal that a vaccine inducing Gag specific CD4+ T cell 
responses has the potential to confer some degree of protection, but other 






APCs  Antigen Presenting Cells  
ARV  Antiretroviral 
ELISPOT Enzyme-Linked Immunosorbent Spot 
BTLA-4 B and T Lymphocyte Attenuator 
CTLA-4 Cytotoxic T-lymphocyte Antigen 4 
CTL  Cytotoxic T-lymphocyte 
HAART Highly Active Antiretroviral Therapy  
HIV-1  Human Immunodeficiency Virus type 1 
HIV-2  Human Immunodeficiency Virus type 2 
HVEM  Herpes Virus Entry Mediator 
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Chapter 1  
1. HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)  
In the 1980s doctors in the USA identified a lentivirus, a subclass of the retrovirus 
family, as the causative agent of a new disease where patients presented with 
lymphadenopathy, opportunistic infections and a marked decrease in the number 
of CD4+ T lymphocytes (CDC, 1981, Coffin et al., 1986). This pathogen was 
subsequently named human immunodeficiency virus-1 (HIV-1) (Barre-Sinoussi et 
al., 1983, Gallo et al., 1983). A related but less pathogenic and immunologically 
different human retrovirus was later discovered and called HIV-2 (Levy, 1993b, 
Levy, 1993a, Gallo, 2002, Clavel et al., 1986). Both HIV-1 and HIV-2 are believed 
to have crossed over from simian immunodeficiency virus (SIV) infected 
chimpanzees to humans in the 20th century in Central West Africa (Gao et al., 
1999, Sharp et al., 2001).  
 
Phylogenetic analyses of the HIV-1 sequences from various regions across the 
world revealed three groups of HIV-1: M (major), O (outlier) and N (non-M or O). 
The M group contains more than 95% of the circulating viruses and consists of 
eight clades (A, B, C, D, F, G, H and J) (Gallo, 2006, Korber et al., 2000, 
Hoffmann et al., 2005).  Currently HIV-1 clade C accounts for 48% of infections 
across the globe, and is most prevalent in Southern Africa, with  5.7 to 6.6 million 
people in South Africa living with HIV-1 (UNAIDS, 2008).  Clade B viruses are 
concentrated mainly in North America and Europe and is the most extensively 





HIV-1 has an envelope glycoprotein composed of two molecules - gp41 (located 
within the viral membrane) and gp120 (protruding from the virus surface) (Burton, 
2006, Ganser-Pornillos et al., 2008, Turner and Summers, 1999, Gelderblom et 
al., 1989). The matrix protein p17 is anchored to the inside of the viral membrane 
and encloses the conical shaped p24 Gag (group-specific antigen) capsid 
protein, which in turn encloses two single stranded RNA molecules and the 
following viral enzymes - reverse transcriptase, integrase and protease 
collectively known as polymerase (Burton, 2006, Ganser-Pornillos et al., 2008, 
Turner and Summers, 1999). In addition, HIV also has six accessory and 
regulatory proteins- nef, vif, vpr, vpu, rev, and tat (Freed, 1998, Gallo, 1988, 
Hoffmann et al., 2005).  
 
Nef downregulates the expression of CD4 co-receptors and MHC Class I 
molecules, and interferes with T cell activation, thereby providing an escape 
mechanism from virus-specific CD8+ cytotoxic T lymphocytes (CTLs) (Hoffmann 
et al., 2005, Turner and Summers, 1999, Aiken et al., 1994, Collins et al., 1998, 
Geyer et al., 2001).  Tat, rev, vif, vpr and vpu all play key roles in the viral 
replication cycle (Calnan et al., 1991, Hoffmann et al., 2005, Rosen and Pavlakis, 
1990, Turner and Summers, 1999, Cullen, 1999, Miller and Sarver, 1997). 
 
An important feature of Vif is that it attaches to a cellular inhibitor called 




which acts specifically on HIV-1 to prevent the synthesis of proviral DNA. By 
binding to APOBEC3G, Vif inhibits its function and therefore promotes viral 
replication (Hoffmann et al., 2005, Sheehy et al., 2003). 
(Barouch et al., 2012, Calattini et al., 2011, Hansen and Caspi, 2009, Hansen et 
al., 2009, Sacha et al., 2009, Seder and Ahmed, 2003, Virgin et al., 2009) 
 
HIV replication cycle 
The gp120 envelope molecules on the viral surface bind to the CD4 receptor and 
to a chemokine co-receptor. The most common chemokine co-receptors utilized 
by HIV-1 are CXCR4 and CCR5, which are expressed predominantly on 
macrophages, dendritic cells and T cells (Hoffmann et al., 2005, Turner and 
Summers, 1999, Rubbert et al., 1998, Ostrowski et al., 1998). A recent study has 
found that gp120 also binds to integrin 4 alpha 7, a transmembrane protein that 
mediates interaction between adhesion molecules, on CD4+ T cells. This 
attachment mediates the migration of CD4+ T cells to the lymphoid tissue in the 
gastrointestinal tract (GIT) and activates the expression of Lymphocyte Function 
Associated Antigen-1 (LFA-1), which in turn mediates the formation of virological 
synapses thereby promoting the dissemination of HIV-1 (Arthos et al., 2008). 
 
The fusion between gp120 and the CD4 receptor on the host cell facilitates the 
injection of the viral contents into the target cell (Gelderblom et al., 1989). 
Several studies have also shown that HIV also utilizes lipid rafts from the host 




and Copeland, 2004). Viral replication and transcription are initiated by reverse 
transcriptase, which copies the single stranded viral RNA into its double stranded 
complementary proviral DNA (Turner and Summers, 1999, Hoffmann et al., 
2005). Since the reverse transcriptase of HIV lacks proof reading mechanisms, 
this step is highly error prone and gives rise to a high number of mutations or 
quasispecies  that enable the virus to escape recognition by the cellular immune 
system (Malim and Emerman, 2001). A cytoplasmic body called TRIM5α binds to 
the HIV Gag capsid protein and accelerated viral uncoating and thus inhibiting 
HIV replication before the reverse transcription step (Hoffmann et al., 2005, 
Stremlau et al., 2004, Li et al., 2006). 
 
In resting infected cells, the proviral DNA accumulates within the cell, integrating 
into the nucleus only once the cell is activated (Siliciano and Siliciano, 2000, 
Douek et al., 2002). The resting infected cells serve as reservoirs of HIV that 
cannot be eliminated even by antiretrovirals (ARVs) (Finzi et al., 1997). They 
pose a threat if antiretroviral therapy is stopped, as they harbour replication 
competent virus that can mutate into ARV resistant strains (Hoffmann et al., 
2005, Finzi et al., 1997). 
 
Upon activation (by antigens, cytokines, mitogens and to a certain extent even gp 
120 itself), the complementary DNA is transported into the nucleus where viral 
integrase incorporates it into the host cell DNA. Transcription of the DNA 




Young, 1998). The production of NFκB, which promotes the transcription of DNA 
into mRNA, is upregulated (Griffin et al., 1989, Nabel and Baltimore, 1987). In 
resting CD4+ T cells, NFκB can be inhibited by a cellular protein Murr1, the 
activity of which correlates with the inhibition of HIV replication in quiescent CD4+ 
T cells (Ganesh et al., 2003, Hoffmann et al., 2005).  The viral mRNA is 
translated into polyproteins, which are then cleaved by viral and cellular 
proteases and assembled into new virions (Hoffmann et al., 2005, Turner and 




2.  OVERVIEW OF THE T-CELL MEDIATED IMMUNE RESPONSE  
CD4+ T lymphocytes (T-helper - Th) are pivotal to the immune system as they 
coordinate the functioning of the adaptive and cellular immune responses while 
CD8+ T cells (cytotoxic T cells - CTLs) are responsible for the killing of infected 
cells (Kim et al., 1985, Cantor and Boyse, 1975, Banchereau and Steinman, 
1998, Harty et al., 2000).  CD4+ T cells are activated by professional antigen 
presenting cells (APCs that comprise B cells, macrophages and dendritic cells - 
DCs) that bear antigenic peptides presented by Major Histocompatibility Complex 
(MHC, also called Human Leukocyte Antigen - HLA) Class II molecules.  CD8+ T 
cells are activated by cells expressing MHC Class I molecules (present on all 
nucleated cells in the body) (Janeway et al., 2005, Abbas and Lichtman, 2003, 
Bretscher and Cohn, 1970, Lafferty and Gill, 1993, Lenschow et al., 1996). 
 
Immature dendritic cells (DCs) take up HIV-1 virions via Dendritic Cell-Specific 
Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) receptors 
within tissue surrounding the skin and mucosal sites. They migrate to the 
lymphoid organs where they develop a mature phenotype and present the virus 
to CD4+ T cells. The interaction between the DC and CD4+ T cell is 
strengthened by the interaction between Inter-Cellular Adhesion Molecule 1 
(ICAM-1) on the APC and Lymphocyte Function Associated Antigen-1 (LFA-1) on 






T cells bind to the antigen/MHC complex via their T cell receptor (TCR) complex 
and either the CD4 or the CD8 co-receptor proteins (Lenschow et al., 1996). The 
α/β chains that form the TCR are generated by the splicing of gene segments 
and chromosomal rearrangements during T cell development. This generates a 
vast repertoire of TCRs capable of responding to a large number of invading 
pathogens (Sompayrac, 2003, Abbas and Lichtman, 2003, Nemazee, 2000). 
 
Upon binding of the MHC-TCR complex, the cytoplasmic end of T cell receptors 
make contact with cholesterol-rich lipid rafts, located inside the plasma 
membrane. These lipid rafts “carry” a large number of downstream signaling 
molecules that ultimately activate the genetic material of the cell via transcription 
(Xavier et al., 1998, Janes et al., 1999).  
 
It has been known for some time that the TCR-MHC interaction on its own is 
insufficient to optimally activate T cells. In recent years there has been a surge in 
studies analyzing costimulatory and inhibitory receptors involved in T cell function 
(Sompayrac, 2003, Lenschow et al., 1996, Crawford et al., 2009). 
 
Effective stimulation and differentiation of naïve T cells is dependent on 
coordinated TCR-MHC interaction (antigens presented by MHC class I bind to 
CD8 TCR and those presented by MHC Class II bind to CD4 TCR), costimulatory 
signaling and inflammatory molecule signaling. Failure to receive a secondary 




in vivo (non-responsive to future antigenic contacts even in the presence of 
costimulatory signals) , or tolerant in vitro (Lenschow et al., 1996, Schwartz et al., 
2003).   
 
Costimulatory and inhibitory molecules are present on both naïve and memory T 
cells and are mainly derived from the immunoglobulin (Ig) superfamily, 
specifically the CD28:B7 and the TNF:TNFR subfamilies. In the first group, CD28 
and ICOS are costimulatory receptors binding to B7.1/B7.2 and ICOSL 
respectively. CTLA4, BTLA4, PD-1, PD-L1 are inhibitory members of the CD28 
subfamily, binding B7.1/B7.2, HVEM, PD-L1/PDL-2 and B7-1 respectively 
(Greenwald et al., 2005). 
 
The TNF:TNFR subfamily consists of the following costimulatory receptors: 
CD40L, OX40, 4-1BB, CD27 and LIGHT, that bind the following stimulatory 
molecules: CD40, OX40L, 4ABBL, CD70 and HVEM respectively (Watts et al., 
2005). This indicates that the same ligands can exert a stimulatory or inhibitory 
effect depending on the receptor that it binds onto.  
 
The receptors listed above are currently considered to be the most important 
costimulatory and inhibitory receptors in modulating T cell function. Recent 
findings have identified several more receptors, among them: LAG-3; 2B4/CD44; 




Siglecs (Crawford et al., 2009). Further research is warranted to develop this 
field. 
 
Once activated in the lymph node, naive CD4+ and CD8+ T cells undergo clonal 
expansion and differentiate into effector T cells which migrate to the site of 
infection. Effector CD8 T cells exert their cytotoxic effect by secreting the 
cytokines IFN-γ, TNFα, IL-2 and the lytic granules – granzyme and perforin. 
Naïve CD4 T cells exposed to antigen differentiate into TH1 or TH2 CD4 T cells 
that secrete either IFN-γ or IL-4. CD4 T cell clonal expansion drives CD8 T cell 
function and B cell activation (Kaech et al., 2002, Sallusto et al., 2004, Messi et 
al., 2003, Ansel et al., 2003). 
 
In acute infection, this usually results in viral clearance after a few days of 
infection. Over the next few weeks, more than ninety percent of the effector T 
cells die during the contraction phase. The surviving T cells differentiate into 
either central memory (TCM-residing in lymph nodes) of effector memory (TEM- 
located at peripheral sites) T cells (Kaech et al., 2002, Sallusto et al., 2004, 
Messi et al., 2003, Ansel et al., 2003). 
 
After antigen clearance, Treg cells (expressing CD4+CD25+FoxP3+) 
downregulate the immune response by inhibiting proliferation of naïve and 
effector T cells. This is accomplished via IL-10 and transforming growth factor-




effector T cells undergo a form of apoptosis termed Activation Induced Cell 
Death (AICD), while a small number differentiate into TCM or TEM cells 
(Sompayrac, 2003, Janeway et al., 2005, Sallusto et al., 2004, Alderson et al., 
1995, Ramsdell et al., 1994). 
 
Both CD4+ and CD8+ TCM cells are referred to as reactive memory cells, are 
located in the secondary lymphoid organs and have little or no immediate effector 
function (Williams and Bevan, 2007). They proliferate and differentiate into 
effector T cells when stimulated by cognate antigens.  TEM cells on the other hand 
are located at the periphery enabling them to exert immediate effector function 
(Sallusto et al., 2004). 
 
Memory T cells are phenotypically and functionally different to naïve and effector 
T cells. They can rapidly differentiate into effector cells; shed and reacquire 
lymph node homing markers (CD62L); have high proliferative capacity; persist 
without antigen stimulation via IL-7 and IL-15 induced homeostatic proliferation 
(Wherry, 2011, Virgin, et al., 2009, Williams, et al., 2007, Jameson, et al., 2009). 
 
The efficient generation of memory CD8 T cells is dependent upon the presence 
of CD4 T helper cells (Sun et al 2003, Janssen et al, 2003). Recent studies on 
LCMV infected mice and HIV infected LTNPs found that virus-specific IL-21 
producing CD4 T cells play a crucial role in maintaining virus-specific CD8 T cell 




important to note that these infections were never cleared but controlled to low 
antigen level.  
 
During chronic viral infection with high levels of viremia, the scenario is slightly 
different. The prolonged and repetitive stimulation of T cells with antigen can 
result in a loss of antigen specific T cell functionality (including proliferation), 
sustained high level expression of inhibitory receptors. Some T cell clones are 
deleted but the majority persists in a non-functional state for extended periods. 
This phenomenon has been termed ‘T cell exhaustion’ (Kaech et al, 2002, 
Wherry, 2011). 
 
T cell exhaustion can be driven by pathways extrinisic to the cell (via 
immunoregulatory cytokines) or intrinsic to the cell (via the expression of 
inhibitory receptors like PD-1). According to recent molecular studies, T cell 
exhaustion may represent a distinct state of T cell differentiation (Wherry, 2011). 
 
T cell exhaustion occurs gradually. In the early stages, CD8 T cells incur losses 
of IL-2 production, proliferative and ex vivo killing capacity, followed by TNF 
production. Severely exhausted CD8 T cells are unable to produce large 
amounts of IFN-γ, beta chemokines or degranulate. At the end phase, the 
exhausted cells are deleted. The level of CD8 T cell exhaustion is positively 
correlated with viral load; amount of antigenic epitopes presented to the T cells; 




and inversely correlated with CD4 T helper cell activity (Wherry, 2011, Virgin et 
al., 2009, Wherry et al., 2004, Wherry et al., 2003). 
 
CD4 T cell exhaustion has not been studied to the same extent as CD8 T cell 
exhaustion. Although the mechanism of CD4 T cell exhaustion is unknown, virus-
specific CD4 T cells have been shown to become dysfunctional during chronic 
viral infections (Wherry, 2011, Kaufmann et al., 2007, Brooks et al., 2005).  Loss 
of CD4 T cell function leads to decreased IL-21 and increased IL-10 levels, which 
in turn directly decreases CTL anti-viral activity (Wherry 2011, Yi etal., 2009, 




3. CD4+ AND CD8+ T CELL IMMUNE RESPONSES TO HIV-1 
Trafficking of HIV bearing DCs to activate CD4+ T cells in the lymph nodes 
allows for the dissemination and establishment of HIV in the host cells (Coleman 
and Wu, 2009).  The resultant infection and extensive loss of the preferentially 
activated CD4+ T cells is the hallmark of HIV-1 infection (Appay and Sauce, 
2008,Douek et al., 2002). HIV-1 infected CD4+ T cells are killed by 
granzyme/perforin and various cytokines secreted by CTLs (Gulzar and 
Copeland, 2004, Hudig et al., 1993); CTL mediated apoptosis  (Rouvier et al., 
1993, Sad et al., 1997) and by the budding of newly synthesized HIV-1 virions 
from the CD4+ T cell (Leonard et al., 1988). A large number of bystander or 
uninfected CD4+ T cells are also killed by apoptotic mediated pathways (Finkel et 
al., 1995). 
Recent studies have found that naïve T cell homeostasis is dependent on IL-7 
produced by T zone fibroblastic reticular cells (Link et al., 2007). 
Murine models show that effective viral specific CD8+ T cell responses are 
dependent on CD4+ T cell activity (Zajac et al., 1998, Shedlock and Shen, 2003, 
Matloubian et al., 1994, Janssen et al., 2003, Sun and Bevan, 2003). Several B 
clade based studies investigating the role of CD4+ and CD8+ T cell activity in 
HIV-1 infection revealed that virus specific CD4+ and CD8+ T cells retain their 
ability to secrete IFN-γ, but in persons with high viral loads HIV-specific CD4+ 
and CD8+ T cells had a reduced proliferative capacity in response to HIV 




Kaufmann et al., 2004, Betts et al., 2001a, Draenert et al., 2004, Addo et al., 
2003, Lichterfeld et al., 2004, Day et al., 2007).  
Apart from secreting cytokines to boost the CTL response, CD4+ Th cells have 
been shown to directly activate CTLs by CD40L binding; enhance CTL activation 
via DC activation, and generate functional memory CD8+ T cells (Janssen et al., 
2003, Sun and Bevan, 2003, Shedlock and Shen, 2003, Ridge et al., 1998, 
Schoenberger et al., 1998, Bennett et al., 1998).  
It has also been well documented that CD4+ T cells secreting IFN-γ only 
represent a skewed cytokine response caused by constant exposure to antigen 
(Boaz et al., 2002, Day and Walker, 2003, Iyasere et al., 2003, Younes et al., 
2003). CD4+ T cells producing both IFN-γ and IL-2 were negatively associated 
with viral load, and low frequencies of IL-2 producing CD4+T cells were 
associated with a reduction in their proliferative capacity.  Taken together, it was 
concluded that HIV-1-specific CD4 T cells in untreated patients with progressive 
disease have a cytokine secreting profile skewed to producing IFN-γ alone that 
renders them relatively non-functional. 
Apart from inducing apoptosis and directly lysing infected cells by 
perforin/granzyme molecules, CD8+ T cells also release macrophage 
inflammaotory proteins (MIP-1 α, MIP-1β); RANTES (regulated upon activation, 
normal T cell expressed and secreted) and cell derived antiviral factor (CAF) 
(Gulzar and Copeland, 2004). The cell surface expression of CD107a on CD8+ T 




(Burkett et al., 2005). Classical early studies showed that CTLs are vital in 
controlling HIV and SIV replication as CD8-depletion of SIV-infected primates 
resulted in high plasma viral load (Ogg et al., 1998). However, most subsequent 
studies employed IFN-γ ELISPOT assays as a measurement of HIV-1 specific 
CD8+ T cell activity and generated conflicting results concerning CD8+ T cell 
responses and viral load (Ogg et al., 1998, Koup et al., 1994, Addo et al., 2003, 
Betts et al., 2001b). 
This discrepancy and the failure of the Merck T cell-based STEP vaccine trial has 
led investigators to reassess T cell immunity, in particular secretion of multiple 
cytokines and anti-viral factors, as well as memory cell phenotyping (Steinbrook, 
2007, Almeida et al., 2007). Although multicolour flow cytometry has made this 
possible, it is not known whether poyfunctional (positive for three or more 
functions - IFN-γ, TNF-α, IL-2, MIP-1β or CD107a) CD8+ T cells are a cause or a 
consequence of low viral load (Brenchley et al., 2008a, Saez-Cirion et al., 2007). 
Recent findings suggest that the HIV suppressive activity of polyfunctional CD8+ 
T cells is related to the antigen load (Almeida et al., 2009). 
A key feature of chronic untreated HIV-1 infection is a state of sustained immune 
activation coupled with ongoing viral replication (Appay and Sauce, 2008). This 
paradox was supported by data showing that increased CD38 levels on CD8+ T 
cells correlated with disease progression (Appay and Sauce, 2008, Giorgi et al., 
1993, Hazenberg et al., 2003).  This chronic state of immune activation accounts 




1. enhanced activation-induced T cell death (Hofer and Speck, 2009) 
2. disruption of T cell homeostasis, including decreased thymic output 
(Moses et al., 1998, Douek et al., 1998) 
3. reduced T cell proliferation (Maini et a, 1999) 
4. aberrant cytokine secretion profile (Harari et al., 2004(Fan et al., 1993) 
5. skewed memory T cell generation (Harari et al., 2004, Burgers et al., 
2009) 
6. reduced regenerative capacity of immune cells ((Brenchley et al., 2006a, 
Brenchley et al., 2006b, Hofer and Speck, 2009, Appay and Sauce, 2008, 
Harari et al., 2004, Burgers et al., 2009, Maini et al., 1999). 
The dysfunctional immune system leads to a large number of CD4+ T cells 
undergoing apoptosis before they expand into effector T cells. CD8+ T cells do 
not seem to follow the exact same fate with a large number of antigen specific 
CTLs undergoing expansion and differentiation into pre-terminally differentiated 
effector cells (CD45RA- CCR7-) (Appay and Sauce, 2008, De Boer et al., 2003, 
Ferreira et al., 2000, Homann et al., 2001, Champagne et al., 2001, Harari et al., 
2004) . 
Another feature of chronic immune activation is the upregulation of PD-1 on virus 
specific T cells reducing their functionality (Sauce et al., 2007). PD-1 expression 
on CD8+ T cells correlated positively with plasma viral load and apoptotic activity 
and inversely with CD4 counts, cytokine production and proliferation (Day et al., 





PD-1 expression on HIV-1 specific CD4+ T cells was also associated with 
disease progression (Day et al., 2006). The inhibitory receptor CTLA-4 is likewise 
associated with HIV-1 disease progression, and correlates negatively with IL-2 
production and positively with viral load and may account for anergic CD4+ T cell 
responses in HIV-1 infection (Kaufmann et al., 2007, Leng et al., 2002, Steiner et 
al., 1999). 
With increased understanding of T cell exhaustion, it is becoming clear that the 
features of untreated chronic HIV-1 infection (high viral load; declining CD4 
counts and constant T cell stimulation), ultimately result in T cell exhaustion. 
However, studies have shown variations to the typical pattern - even towards the 
end stages of HIV-1 infection, IFN-γ producing T cells do persist, but with 
diminished capacity to produce IL-2, TNFα, proliferate and exert their cytotoxic 
effect (Wherry, 2011, Betts et al., 2006). This phenomenon could explain the lack 
of correlation between the magnitude of IFN-γ producing T cells and viral load 
(Addo et al, 2003, Ramduth et al 2009). 
The past few years have also seen much coverage of Tregs in HIV-1 infection. 
Two characteristics of Tregs have emerged:  
(A) Tregs have an inhibitory effect on effector T cells mediating antiviral 
activity; in particular they inhibit the proliferative response to HIV antigens 




(B) Tregs reduce the level of immune activation, which could have beneficial 
effects for HIV-1 immunity (Sempere et al., 2007)   
There is also evidence that Tregs skew the CD4+ T cell response away from a 
Th1 to a Th2 type response (Tsunemi et al., 2005).  Furthermore, Treg cell 
numbers were increased in progressors compared to non-progressors and 
appear immune to apoptosis (Sempere et al., 2007). However, the field is also 
controversial with the markers identifying Tregs undergoing constant revision. 
The current consensus to identify Tregs are the presence of CD4+, CD25high, 
FoxP3+ and CD127low (Sempere et al., 2007), (Ji and Cloyd, 2009, Kinter et al., 
2004, Nixon et al., 2005, Tsunemi et al., 2005, Weiss et al., 2004). This has led 
to no conclusive evidence for the role that Tregs play in controlling or promoting 
HIV-1 infection.  
In addition, several recent studies have found that controlled HIV-1 infection is 
associated with serum detectable levels of IL-21 produced by CD4 T helper cells 
and the presence of the IL-21 receptor on effector CD8 T cells. (Chevalier et al, 
2011, Lannello et al, 2008, Yeu et al, 2010). Taken together, these findings show 
that although HIV-1 specific T cells may be present in large numbers, the quality 
of these cells in mediating an immune response is compromised. 
Adding to the complexity of the insufficient immune control is the ability of HIV-1 
to escape recognition by CTLs in response to immune selection pressure exerted 
by CTLs (Price et al., 1997,McMichael and Rowland-Jones, 2001). Given its high 




mutants occurs readily in HIV-1 infection (McMichael and Rowland-Jones, 2001).  
There is mounting evidence that mutations generated are not random though, but 
influenced by the HLA type of the infected individual (Goulder and Watkins, 2008, 
Kiepiela et al., 2004, Leslie et al., 2005, Leslie et al., 2004, Ngumbela et al., 
2008, Thobakgale et al., 2009). It is perturbing to note that on a global scale, 
there is an accumulation of HIV escape mutations in populations with a high HLA 
selection pressure, indicating the evolutionary adaptation of HIV to it host (Payne 
et al., 2009, Kawashima et al., 2009). 
Recently substantial data has suggested that primary HIV-1 and SIV infection 
occur in gut associated lymphoid tissue (GALT) where the DCs present the virus 
to resting central memory (CCR5+) CD4+ T cells. This leads to massive 
depletion of CCR5+ CD4+ T cells by direct infection, apoptosis or direct killing by 
CTLs and establishes a reservoir of HIV-1 that cannot be eradicated even with 
HAART (Brenchley et al., 2006a, Veazey et al., 1998, Brenchley et al., 2004, 
Sankaran et al., 2008, Guadalupe et al., 2003, Mehandru et al., 2004, Anton et 
al., 2003).    
However, the idea that HIV-1 induces a massive early onslaught on CD4+ 
memory cell numbers has been challenged by a study on sooty mangabeys 
showing that the memory CD4+ T cells targeted in the GALT are highly activated 
short-lived effector memory CD4+ T cells and not the central memory 
CCR5+CD4+ T cells  (Grossman et al., 2006). The gradual loss of CD4+ T cells 




CD4+ T cell turnover, chronic exposure to HIV-1 and the generation of 
dysfunctional memory CD4+ T cells CD4+ T cell rather than direct killing in the 
first few weeks of infection (Grossman et al., 2006, Kelleher and Zaunders, 
2006).  
New data suggests that CD4+ Th17 cells could be the target in the GALT as they 
are found in low frequencies in acute SIV and in HIV infection and correlate 
negatively with plasma virus level (Cecchinato et al., 2008, Brenchley et al., 
2008b).  In fact, the compromised immune integrity in the GALT allows for the 
translocation of microbial products from the gastrointestinal tract, which can 
account for the chronic state of heightened immune activation observed in HIV-1 
infection (Brenchley et al., 2006b).  
The obliteration of memory CD4+ T cells severely impacts on the ability of the 
adaptive immune system to ward off pathogens it had previously encountered, 
thereby permitting the establishment of opportunistic infections that characterize 
HIV/AIDS infections (Veazey and Lackner, 2005, Mattapallil et al., 2005, Haase, 
2005). 
Two recent SIV vaccine studies have reported some success in generating 
protective immunity in rhesus monkeys. Hansen et al constructed a Rhesus 
Cytomegalovirus vector (RhCMV) that incorporated the SIV Gag, Nef-Tat-Rev 
and Env proteins. Rhesus macaques were vaccinated either with RhCMV vector 
alone or with RhCMV and adenovirus 5 (Ad5) vector. Both groups generated and 




sites, and were able to control viral replication to below detectable levels when 
challenged with the SIVmaq239 strain (Hansen et al, 2009, Hansen et al, 2011). 
The second study by Barouch et al vaccinated rhesus macaques with the 
Adenovirus/poxvirus and adenovirus/adenovirus-vector-based vaccines 
containing Gag, Pol and Env from the SIVSME543 strain. The vaccine reduced the 
probability of infection by 80% (Barouch et al, 2012). 
Thus given the pivotal role that T cells play in the immune system and that sub-
Saharan Africa bears the brunt of HIV-1 infection, it is imperative to characterise 
the relationship between HIV-1 infection and T cells in this setting (UNAIDS, 
2008).  The few immunologic studies of clade C HIV-1 infection published thus 
far have been limited to the characterization of CD8+ T cell responses in adult 
infection (Kiepiela et al., 2004, Kiepiela et al., 2007, Ngumbela et al., 2008, 
Goulder et al., 2001b, Thobakgale et al., 2007, Novitsky et al., 2006, Gray et al., 
1999, Gray et al., 2009). Thus characterizing HIV-1 specific CD4+ T cell activity 
in adults and infants infected with clade C virus is important in determining the 





4. T CELL RESPONSES IN PAEDIATRIC HIV INFECTION 
At the time of this study, 72 000 HIV-1 infected infants were born each year in 
South Africa, and 40% of deaths in children under 5 years were AIDS related 
(UNICEF, 2005, DOH RSA 2004). Antiretroviral drugs were provided according 
to criteria stipulated by the South African Department of Health - only when the 
CD4 percentage was <20% in infants below 18 months of age and <15% in those 
older than 18 months 13.  
Although there have been several investigations into pediatric immune responses 
at a cellular level, these have been limited in the sensitivity of the assays used 
(ELISAs measuring secreted IL-2 from cord blood), and confined to CD8+ T cell 
responses in acutely infected infants, and to CD4+ and CD8+ T cell activity in 
chronically infected children (Kuhn et al., 2001a, Kuhn et al., 2002, Kuhn et al., 
2001b, Kuhn et al., 2001c, Kuhn et al., 2007, Thobakgale et al., 2009, 
Thobakgale et al., 2007, Persaud et al., 2000, Farquhar et al., 2005, Lohman et 
al., 2005, Slyker et al., 2005).  HIV-1 specific T cell responses were rarely 
detected in infants younger than 24 months, with the magnitude and breadth of 
responses increasing with age (Predergast et al, 2011).   
Just as in adult infection, certain MHC class I molecules influence disease 
progression by driving the virus to mutate into less fit strains. Slow progressor 
infants were found to have at least one protective HLA class I allele (B57, B5801, 
B8101) or have inherited a less fit virus from a mother possessing a protective 




OUTLINE OF THESIS 
The mechanistic interaction between CD4+ T cells and HIV-1 has been 
described in the first part of this thesis. Previous literature has alluded to the 
possible vital role played by CD4+ T cells in controlling HIV-1 infection. Chapter 
2 describes the simultaneous quantification of CD4+ and CD8+ IFN-γ T cell 
responses. These responses were mapped to all HIV-1 proteins in a cohort of 
chronically infected, therapy-naïve adults and the relationship between HIV-1 
specific CD4+ and CD8+ T cell activity was investigated. In Chapter 3  the study 
was extended to the developing immune system by assessing HIV-1 specific 
CD4+ T cell  cytokine activity (IFN-γ, IL-2 and TNF-α) and proliferative responses 
in acutely infected infants. In addition, the effect of early HAART on the HIV-1 
specific immune responses was also investigated. Chapter 4 focused on 
identifying particular HIV-1 CD4+ T cell epitopes and their association with viral 
load.  Dual cytokine expression and cross clade activity was also investigated. 
Chapter 5 is a coauthor paper characterizing CD8+ T cell responses in infants 
from birth, while chapter 6 investigated the relationship between HIV protein 
specific responses and viral load. The investigation of these aspects of HIV-1 
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An effective cellular mediated immune response against infectious diseases 
requires CD4+ and CD8+ T cells functioning in concert against pathogens, 
leading us to hypothesize that HIV-1 specific CD4+ T cell responses are 
associated with disease control in HIV-1 clade C infection. Our studies found that 
in untreated adults, CD4+ T cell responses correlated with CD8+ T cell 
responses and that the targeting of the Gag region was associated with disease 
control (chapter 2). In pediatric subjects, we found Gag to be the earliest HIV 
protein targeted and the level of the immune response was determined by 
antigen load (chapter 3). Returning to the adult cohort, we were able to identify 
specific CD4+ epitopes (the majority of which were clustered in the Gag region) 
and found that the breadth of the response was associated with viral control 
(chapter 4). We discuss these findings in the context of current literature and 
vaccine development strategies, as well as future directions of CD4+ T cell 
research in HIV immunopathogenesis. 
 
Identification of CD4+ T cell Responses in Clade C Infection 
At the onset on the study, CD4+ T cell responses in HIV-1 clade C infection had 
been poorly characterized. The studies that had been conducted investigated 
CD4+ T cell responses to a few envelope proteins in cord blood using traditional 
ELISAs (Kuhn et al., 2001b, Kuhn et al., 2001c) and identified CD8+ antigen 
specific responses by an IFN- γ  Elispot assay (Masemola et al., 2004, Goulder 
et al., 2000, Goulder et al., 2001a). To better characterize HIV-specific CD4+ T 
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cell responses in clade C infection in both adult and pediatric subjects, we 
utilized a flow cytometry based technique to identify protein specific CD4+ IFN-γ 
responses and then proceeded to identify individual antigen specific responses 
by Elispot.  
 
Elispot and ICS have become standard techniques in the assessment of antigen 
specific cytokine responses (Barouch and Letvin, 2000a, Barouch and Letvin, 
2000b, Liu et al., 2009, Barouch et al., 2009, Addo et al., 2003, Goulder et al., 
2001, Gray et al., 1999). Each technique has its respective advantages and 
shortcomings. The Elispot assay is extremely sensitive, capable of detecting 
0.01% cytokine producing cells and can be performed with as little as 50 000 
cells. However, unlike in ICS, no phenotyping can be conducted during the 
assay, necessitating prior purification to isolate responses from a particular 
cellular subset.  In our study, this was the best technique to identify individual 
antigen responses almost immediately ex vivo utilizing a limited number of cells.  
 
The ICS assay on the other hand requires a larger number of cells to begin with 
(0.5 to 1 X 106) ensuring that a statistically significant number are available for 
acquisition post several wash steps. At the time of performing the ICS assays, 
the sensitivity of the assay in our lab (determined by running HIV negative 
controls) was lower than the Elispot assay, with responses in our control subjects 
ranging from 0.01-0.03%. Given their complementary characteristics, we 
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employed both techniques to comprehensively identify and confirm HIV-1 specific 
CD4+ T cell epitopes.  
We considered culturing CD4+ T cells with protein peptide pools before 
conducting the Elispot or ICS but this ran the risk of growing out the dominant 
antigen specific clones, thereby masking the low magnitude responses.  We then 
considered the use of MHC Class II tetramers.  Previous studies found that 
combining tetramer staining with prior cell enrichment techniques; can increase 
the detection of low frequency antigen specific cells (Scriba et al., 2005, Ceconni 
et al., 2008) However, in comparison to MHC Class I  tetramers, MHC Class II 
tetramers are not as stable mainly because: 
1. the conjugation of Class II tetramers does not always yield stable 
structures 
2. the reorganization of the TCR on the plasma membrane upon T cell 
activation influences the binding of the tetramers 
3. there is variability in the degree of homogenous binding of the CD4 
epitope to a monomer arm (Ceconni et al., 2008). 
 
The level of sensitivity of MHC Class I tetramers can be as low as 0.02% and 
have been successfully utilized in identifying low frequency CD8+ T cell clones in 
chronic clade C infection (Day et al., 2006, Day et al., 2007, Kelleher and 
Rowland-Jones, 2000). In the context of tetramer staining, an important 
shortcoming of CD4+ T cell epitopes is that they are promiscuous in their binding 
to multiple MHC Class II alleles which renders the specificity and sensitivity of 
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MHC Class II tetramers in CD8+ T cell depleted cells questionable (Kaufmann et 
al., 2004).  Even if more CD4 epitopes were to be defined, HLA restriction might 
be difficult, due to the promiscuous nature of CD4+ T cell epitopes. Another 
shortfall is that tetramer staining does not measure any functionality but merely 
quantifies the number of antigen specific cells (Kelleher and Rowland-Jones, 
2000). Apart from these factors, tetramer synthesis is a costly and labour 
intensive process, making its implementation for comprehensive studies difficult. 
 
Association between CD4+ T cell Responses, CD8+ T cell Responses and 
Clinical Parameters in Chronic Clade C HIV-1 Infection 
Consistent with previous clade B studies we found that CD4+ IFN-γ responses 
persisted in chronic infection (Pitcher et al., 1999) and correlated positively with 
CD8+ IFN-γ responses. Despite this association, we found no significant 
relationship between the CD4+ T cell IFN-γ responses and viral loads and CD4 
counts.  This can be explained by several studies which have found that IFN-γ 
may not be a marker of effective CD4+ T cell activity but that antigen specific 
CD4+ T cells producing both IFN-γ and IL-2 concomitantly are correlated with 
slower disease progression (Boaz et al., 2002, Harari et al., 2004). Chronic 
exposure to antigen, as in the case of HIV, tends to skew cytokine production to 
the exhausted non-functional IFN-γ only, pre-terminally differentiated memory 
phenotype, compromises their capacity to control HIV replication (Harari et al., 




A caveat of our study was quantifying CD4+ T cell activity by IFN-γ production 
only. A subsequent study which employed a variation of the intracellular cytokine 
technique and defined CD4+ T cell activity by IFN-γ and IL-2 production in clade 
C infection also investigated these relationships but arrived at contrasting 
conclusions (Shalekoff et al., 2008). This study found no relationship between the 
magnitude of HIV-1 specific CD4+ and CD8+ T cell responses, possibly due to 
the analysis of dual cytokine (IFN-γ/IL-2) producing T cells. Similar to our results 
though, they found HIV-specific CD8+ T cell responses to be of a higher 
magnitude than that of CD4+ T cells. This observation may be due to the 
extensive loss of HIV specific CD4+ T cells during infection and to the difference 
in sizes of the antigenic T cell pools – the number of activated CD4+ T cells is 
much smaller that of the CD8+ T cell pool (Kaech et al, 2002, Wherry, 2011). 
Also, IFN-γ producing CD4+ T cells are believed to be TEM cells found at 
peripheral sites (Seder et al 2003). Since TCM cells were not analyzed, we do not 
have a comprehensive analysis of CD4+ T cell function in our cohort.  
 
Taking into account recent findings on the role of inhibitory T cell receptors (such 
as PD-1 and CTLA-4) and T cell exhaustion, we can hypothesize that the 
chronically infected, untreated cohort we studied display the classical signs of T 
cell exhaustion - skewed cytokine profile to IFN- γ only secretion, lack of 
proliferative responses, uncontrolled viral replication and large number of 
antigens presented to T cells (Wherry, 2011, Virgin et al., 2009, Wherry et al., 




Further definition of HIV-T cell immunology could benefit by employing more 
sensitive assays like the viral inhibition assay coupled with kinetic studies for 
both CD4+ and CD8+ T cell activity and in situ tetramer hybridization (ISTH) 
which combines in situ tetramer (IST) and in situ hybridization (ISH). Recent 
findings from these techniques found that control of SIV and LCMV infections 
correlated with the magnitude of effector T cell responses generated very early in 
the course of infection (Li et al., 2009, (Spentzou et al., 2010). Taken a step 
further, studies by Hansen et al on RhCMV vectors carrying SIV encoding genes 
found that the generation of effector memory T cells during early infection had 
resulted in some level of protection when challenged with SIV (Hansen et al, 
2011). 
 
Immunodominance of Gag-Specific T cell Responses in Untreated Chronic 
Clade C Infection and Detection of Cross Clade Responses  
Our initial study showed a dominance of Gag-specific CD8+ T cell responses 
was associated with lower levels of viremia. This was later extrapolated to a 
larger cohort and epitope specific analysis, which confirmed our findings 
(Kiepiela et al., 2007). The study found an inverse relationship between the 
breadth of Gag-specific responses and viral load, and a positive association 
between the breadth of envelope responses and viremia (Kiepiela et al., 2007). 
These conclusions were independent of HLA type and epitope variation and the 
observation adds weight to previous studies which proposed the inclusion of Gag 
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as a major immunogen in an HIV vaccine (Leslie et al., 2005, Addo et al., 2003, 
Kaufmann et al., 2004, Ramduth et al., 2005, McKinney et al., 2004). A following 
study on clade C infection confirmed Gag to be the dominant protein targeted by 
both CD4+ and CD8+ T cells and Gag responders to have a lower viral load than 
non-Gag responders (Shalekoff et al., 2008). 
 
However, we have to be cautious not to interpret these as data as showing that 
Gag-specific responses driving down the viral load as this is a cross sectional 
study of chronic infection. Indeed recent SIV vaccine studies by Barouch et al 
found that the inclusion of the Env protein was important in reducing viral set 
point and conferred protection to subsequent SIV challenge. Another recent 
finding is that during chronic HIV infection, IL-6 mediates the differentiation of 
virus specific CD4+ T helper cells to T follicular (TFH) cells, which enhanced 
lymph node germinal centre activity, which in turn helped sustain B cell activity in 
the lymph nodes. It remains to be investigated whether the enhanced B cell 
activity results in increased neutralization antibody function against HIV Envelope 
(Harker et al, 2011 Fahey et al, 2011). 
 
Expanding on our first study which identified CD4+ T cell responses to whole 
peptide pools, we conducted whole genome screening to identify individual 
epitopes. Here we found a clustering of HIV-1 specific CD4+ T cell epitopes in 
the Gag region and an inverse correlation between the breadth of the responses 
and viral load. Unlike the clade B CD4+ T cell epitope mapping study, Nef was 
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not the dominant target of CD4+ T cells This could be due to differences in the 
disease and antiretroviral treatment states of the subjects recruited, as the clade 
B study analyzed acutely infected patients and patients undergoing Structured 
Treatment Interruption (STI) while our cohort comprised therapy naïve patients 
(Kaufmann et al., 2004). 
 
A striking observation was that one of the most frequently targeted CD4+ 
epitopes (YVDRFFKTLRAEQATQDV) is a p24 Gag peptide spanning part of the 
Major Homology Region (MHR). The MHR displays significant homology among 
multiple genre of retroviruses, with mutations in this region resulting in viral 
particles that have defects in viral assembly, maturation and infectivity (Freed, 
1998). This particular peptide was shown to be frequently targeted in clades B 
and A/G infections and displayed a high degree of cross reactivity between HIV-1 
and HIV-2 infected individuals (Kaufmann et al., 2004, Ondondo et al., 2008). 
Individuals in our study with a response to this peptide also recognized the clade 
B sequence with an equal magnitude (Ramduth et al., 2009), probably due to 
similar biochemical properties between these peptides.  
 
The recognition of CD4+ T cell epitopes across multiple clades by the same 
subject has been investigated by a large number of studies and has yielded 
positive results (Gupta et al., 2006, Norris et al., 2004, De Groot et al., 2004, 
Keating et al., 2002, Betts et al., 1997, Boyer et al., 1998, Gotch, 1998). This 
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feature can be exploited in vaccine design and vaccine testing as it overcomes 
the obstacle of synthesizing vaccines for each clade (Garber et al., 2004). 
 
HIV-1 specific CD4+ T cell Responses in Acutely Infected Infants 
Although there have been several investigations into pediatric immune responses 
at a cellular level, these have been limited in the sensitivity of the assays used 
(ELISAs measuring secreted IL-2 from cord blood), and confined to CD8+ T cell 
responses in acutely infected infants, and to CD4+ and CD8+ T cell activity in 
chronically infected children (Kuhn et al., 2001a, Kuhn et al., 2002, Kuhn et al., 
2001b, Kuhn et al., 2001c, Kuhn et al., 2007, Thobakgale et al., 2009, 
Thobakgale et al., 2007, Persaud et al., 2000, Farquhar et al., 2005, Lohman et 
al., 2005, Slyker et al., 2005, Prendergast et al, 2011).   
Since there had been no reported data on CD4+ T cell responses in acutely 
infected infants, we investigated multiple cytokine production and proliferative 
responses in treated and untreated acutely infected infants (Ramduth et al., 
2008).  
 
Cytokine levels in HIV-1 infected untreated infants (IFN-γ, IL-2 and TNF-α) were 
detected at very low frequencies mainly to the conserved Gag and Pol proteins, 
and not to the envelope protein. The relative lack of cytokine responses in 
comparison to adult HIV-1 infection, with 70% of adults having detectable IFN-γ 
response (Ramduth et al., 2009), could be due to a decreased capacity of the 
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neonatal immune system to produce cytokines (Holt, 2003, Lewis et al., 1986, 
Wilson et al., 1986). However in our cohort, this may be restricted to CD4+ T cell 
responses, as HIV-1 specific CD8+ T cell responses were detected in 70% of 
infected infants (Thobakgale et al., 2007). 
 
Once again Gag was the dominant target of IFN-γ, IL-2 and TNF-α producing 
CD4+ T cells and was the detected as early as day 6 in an in-utero infected 
infant, suggesting that even in-utero, Gag is highly immunogenic. However, the 
envelope protein was targeted more frequently than Gag by CD8+ T cells 
(Thobakgale et al., 2007), indicating a potential disconnect between the CD4+ 
and CD8+ immune responses in neonatal HIV infection. It is important that such 
preferential targeting not be viewed in isolation, but further studies investigating 
cellular immunity also investigate innate immune responses. The cells 
constituting the innate immune system also act as professional APCs to CD4+ T 
cells and their antigen processing may produce different antigenic peptides to 
those produced by MHC Class I bearing cells.   
 
IFN-γ Gag-specific responses were detected sporadically in infants receiving 
treatment and increased in magnitude following treatment cessation, suggesting 
that the level of cytokine response is mediated by antigen load. However, Gag-
specific responses were observed intermittently in the untreated infants, 
indicating a dysfunction in CD4+ T cells chronically exposed to high levels of 
antigen. Despite the increase in the magnitude of Gag-specific responses after 
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stopping treatment, the majority of infants had to resume therapy by 24 months 
of age, implying that the CD4+ Gag-specific IFN-γ responses alone may not 
exert a long term protective effect but could potentially play a role in modulating 
the viral set point. 
 
Since HIV has been shown to preferentially infect activated CD4+ T cells, a 
study investigating the expression of activation markers on CD4+ T cells could 
yield valuable information. A study which was conducted on adults found that a 
history of high immune activation (due to the presence of other pathogens) led 
to a greater loss of CD4+ T cells during the early stages of infection. They also 
observed that higher levels of CD4counts prior to infection led to a greater loss 
of CD4+ T cells. Infants may have an immune system that is continuously 
activated as they adapt to their environment. Associated with a higher absolute 
number of CD4+ T cells, these are factors which could provide the perfect 
environment for HIV replication which in turn skews the functioning of the 
immune system.  
 
An unreported observation is where we compared the HIV-specific IFN-γ CD4 
responses in eight infants and nine adults with viral loads >100 000 copies/ul. 
We found no significant differences in the magnitudes of the responses (p=0.66 
Student T test). It would be interesting to investigate whether these groups 





Implications for Cell Mediated Vaccine Design and Future Perspectives 
Apart from inducing poor cellular immunity, HIV-1 envelope protein also elicits a 
suboptimal humoral response, as the constantly mutating virus successfully 
evades neutralizing antibodies (Wyatt et al., 1998, Wyatt and Sodroski, 1998). It 
was therefore not surprising that the VaxGen trial which aimed to induce 
neutralizing antibodies failed to protect against HIV infection (Veljkovic et al., 
2003, Billich, 2004).  
 
T cell responses though have the potential to be effective therapeutic vaccines 
as the presence of these responses are associated with a reduced rate of 
disease progression, and lower viral set points as demonstrated in SIV primate 
investigations (Barouch and Letvin, 2000a, Barouch and Letvin, 2000b, Liu et al., 
2009, Barouch et al., 2009). A low viral set point also reduces transmission, as 
high viral loads correlate with high transmission rates (Gray et al., 2001, Shiver 
and Emini, 2004, Coll et al., 1997, Khouri et al., 1995, O'Shea et al., 1998). This 
would in turn slow the spread of the pandemic (Garber et al., 2004). 
 
Thus identifying HIV-1 epitopes, and in particular Gag epitopes associated with 
immune control, provides the relevant information for designing a synthetic 
peptide vaccine (Letvin, 2002, Letvin et al., 2002, Sahni and Nagendra, 2004). A 
number of studies have focused on defining HIV-1 specific CD8+ T cell epitopes 
in both clade B and C HIV-1 infections, (Addo et al., 2003, Goulder et al., 2001a, 
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Gray et al., 1999, Kiepiela et al., 2004, Novitsky et al., 2001, Masemola et al., 
2004), while very few have looked at identifying HIV-1 specific CD4+ T cell 
epitopes, and none defining HIV-specific CD4 T cell epitopes targeted in clade C 
infection (Boaz et al., 2003, Kaufmann et al., 2004).  
 
Our research has indicated that IFN-γ secreting Gag-specific CD4+ T cell 
responses are immunodominant in untreated clade C infection, are associated 
with viral control and that CD4+ T cell responses are directed against multiple 
epitopes. However, what needs to be determined is whether these responses are 
the mediators of control or a consequence thereof. A possible approach to this 
conundrum would be to track HIV-1 specific CD4+ T cell activity from the very 
early stages of acute infection. In conjunction with multiple phenotypic analyses - 
host genetic factors (in particular MHC Class II alleles), neutralizing antibody 
studies, viral fitness assays and host cellular protein analyses will need to be 
undertaken in a longitudinal study.  Determining the level of activation by cell 
surface markers (eg CD38) and evaluating the number of T cell Receptor 
Excision Circles (TRECs) would shed light on whether the sub-Saharan 
population has a higher level of immune activation (due to exposure to more 
pathogens) which facilitates HIV infection and replication.  
 
In addition, more sensitive techniques are required to detect and characterize 
this cellular immune response (particularly CD4+ T cell responses) at mucosal 
sites (Coombs et al., 2003). Present data indicate that Gag-specific CD8+ T cells 
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in the rectal mucosa are capable of eliciting effector functions (Critchfield et al., 
2007). However, increased levels of HIV-1 specific CD8+ T cells in the cervix of 
chronically infected women did not inhibit viral shedding in mucosal tissue 
(Gumbi et al., 2008). This implies that the field of mucosal immunity requires 
further investigation since a vaccine capable of eliciting cell mediated immunity 
and conferring protection at mucosal sites, may reduce the rates of horizontal 
and vertical HIV transmission (Gupta and Klasse, 2006).  
 
Despite extensive research into the role of T-regulatory (Treg) cells in HIV-1 
infection, there is no conclusive evidence that these cells play a pivotal role in 
either inhibiting or augmenting HIV replication. There is some evidence that  
natural Tregs (nTregs) can dampen  HIV-1 specific immune responses (resulting 
in high viral loads), as was found in a Ugandan study on therapy naïve 
individuals (Eggena et al., 2005). Other studies indicate that nTregs reduce 
cellular activation, which in turn limits the rate of infection (Weiss et al., 2004).  
 
Inducible T-regs (iTregs) are comprised of two subsets: Tr1 and Th3. Both 
subsets function in the gastrointestinal tract, are activated by cytokines (IL-10, 
TGF-β, IL-4, IFN-γ, IL-5 and IL-2 and suppress effector T cell function via 





TGF-β along with (IL-6) is also the cytokine involved in the generation of the 
newly characterized Th17 CD4+ T cells, an additional effector lineage of CD4+ T 
cells (Harrington et al., 2005, Weaver and Murphy, 2007, Acosta-Rodriguez et 
al., 2007a, Nowak et al., 2009). Studies of HIV-1 infection in the gastrointestinal 
tract (GIT), found that Th17 CD4+ T cells are infected, though not preferentially 
so; a skewing of Th17 cells towards a Th1 phenotype with maturation and 
substantial loss of Th17 cells from the GIT (Cecchinato et al., 2008, Brenchley et 
al., 2008b, Hofer and Speck, 2009, Locksley, 2009). The findings imply that 
overall loss of Th17 cells contributes to the compromised integrity of the mucosal 
membrane, leading to an activated immune system.  
 
In addition, several recent studies have found that controlled HIV-1 infection is 
associated with serum detectable levels of IL-21 produced by CD4 T helper cells 
and the presence of the IL-21 receptor on effector CD8 T cells. (Chevalier et al, 
2011, Lannello et al, 2008, Yeu et al, 2010). Taken together, these findings show 
that although HIV-1 specific T cells may be present in large numbers, the quality 
of these cells in mediating an immune response is compromised. 
 
The immunodominance of Gag is also worthy of more rigorous investigation. A 
recent finding was that the mutations in one of the Gag cleavage sites resulted in 
a 50% reduction in viral infectivity (Lee et al., 2009). Thus new avenues in 
antiretroviral therapy research would be to investigate compounds that inhibit 





The frequency of HIV-1specific CD4+ T cell responses is much lower than HIV-1 
specific CD8+ T cell responses in untreated pediatric and adult infection. This 
can be expected given that CD4+ T cells are not the primary mediators of the 
cellular response against viral infections. However, very recent data has revealed 
that CD4 T cells can exert a cytotoxic effect in addition to their helper activity. SIV 
studies revealed that Gag and Nef specific CD4 T cells were able to kill virus 
infected macrophages, which resulted in lower viral set point (Sacha et al, 2009). 
A very recent longitudinal study conducted on untreated acutely  HIV-1  infected 
subjects found CD4 T cells that killed virus infected cells by secreting granzyme 
A early in infection resulted in controlled infection and slower progression to full 
blown AIDS (Soghoian et al, 2012).   Further characterization of CD4+ T cell 
activity in long term non progressor controllers utilizing more sensitive and 
precise technology has the potential to shed light on correlates of immune 
protection that can in turn guide the development of protective vaccines.  
 
In addition, characterization of CD4+ and CD8+ responses in our subjects to 
other chronic infections such as HCV, EBV, CMV and TB (currently 
approximately 30% of HIV positive subjects in South Africa are co infected with 
TB) would be an important comparison to HIV-1 specific immune responses. 
Characterizing CD4+ T cell responses on a per epitope level in models of viral 
control versus uncontrolled viral replication would provide insight on the immune 
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status of our cohorts. Given their exposure to a higher number of pathogens 
compared to subjects in developed countries, our cohorts may have a greater 
state of immune activation; it is therefore worthwhile studying how this 
heightened state of activation modulates the immune response to HIV.   
A current limitation in the field is the lack of guidelines in establishing cut-off 
values in the Elispot and ICS assays. The generally accepted approach for a 
response to be positive in Elispot assay is that the test wells must have at least 
50 SFCs/106 PBMC and be twice the background signal (Karlsson A. C., 2003). 
For the ICS assay, the background response in HIV-1 negative subjects is 
measured and the standard deviation calculated. A response that was 2SD 
above the mean background (post correction for non specific response as 
detected in unstimulated control wells of the test subjects) was considered 
positive (Karlsson A. C., 2003). Our criteria for a positive response here was 3SD 
above background of the unstimulated control wells, ensuring that robust 
responses were evaluated. This discrepancy highlights a need for standardizing 
the method to define negative responses as these assays have become 
essential in screening vaccine candidates. 
 
There is accumulating evidence that the effectiveness of the immune response 
against HIV-1 is influenced by population genetics, and given that clade C 
infections account for the highest number of HIV-1 infections worldwide (Sub-
Saharan Africa, India and Southeast Asia), it is imperative that basic science 
research be conducted on clade C HIV-1 infection (Kawashima et al., 2009, 
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Kiepiela et al., 2007, Payne et al., 2009, UNAIDS, 2008). Since the prevalence of 
HIV-1 is highest in developing countries that are unable to provide ARVs to all 
infected patients, the development of a vaccine is critical (Letvin, 2006). 
 
Our studies have contributed to HIV vaccine development by identifying 
immunodominant HIV-1 epitopes and characterized the cytokine secreting profile 
of HIV-1 specific CD4 T cells.  MHC class II tetramers and polychromatic flow 
cytometry can be used to study low frequency HIV responses in greater detail, 
which also contributes to our comprehension of the immune system. 
 
From the findings listed in this thesis, our data support the idea that the 
qualitative (parameters are not yet fully defined) and not quantitative differences 
in CD4 T cell functions differentiate effective from dysfunctional HIV-1 specific 
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